Braveheart Bio

BRVE · NASDAQ

$21.44−$0.04 (−0.19%)TodayMarket closed · Oct 23, 7:30 PM ET

Prev close $21.48

BRVE analyst rating

BuyConsensus of 5 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy5
Hold0
Underperform0
Sell0

12-month price target · 6 analysts

Average $46.15 (+115.3% upside)

Low: $40.40
Now: $21.44
High: $50.40

Upgrades and downgrades

The latest rating actions, newest first

BRVE analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Cantor Fitzgerald	Oct 20, 2026	Maintains	Overweight	$40.00	36%
Goldman Sachs	Aug 31, 2026	Initiates	Buy	$48.00	47%
TD Cowen	Aug 31, 2026	Initiates	Buy	—	47%
Jefferies	Aug 31, 2026	Initiates	Buy	$48.00	—
Cantor Fitzgerald	Aug 31, 2026	Initiates	Overweight	$40.00	36%
Stifel	Aug 31, 2026	Initiates	Buy	$45.00	36%

The case for and against

Updated Oct 22, 2026

Bull case

Braveheart Bio is supported by a compelling clinical and commercial setup for BHB-1893, whose phase 2 data showed ~5.5-6 point placebo-adjusted KCCQ gains at Week 12, plus improvements in pVO₂, diastolic relaxation, and early LV remodeling signals. The company’s cash from the IPO raised about $440M appears sufficient to fund both global phase 3 programs through completion into ~2029, reducing near-term financing and dilution risk while several de-risking catalysts arrive in 1H27 and 2H27. Fundamentally, the bullish case rests on nHCM differentiation in a whitespace market and on oHCM share gains through a simpler one-step titration profile that could make a validated drug class easier to use and commercially attractive.

Bear case

Braveheart Bio is a high-risk clinical-stage biotech because its lead asset, BHB-1893, has only shown encouraging KCCQ and remodeling signals in a relatively small 12-week phase 2 study, leaving the global phase 3 NOBLEHEART-HCM trial to prove the effect is durable and scalable. The data also show meaningful variability concerns, with about 35% of ODYSSEY patients needing down-titration and/or discontinuation, including 22% due to LVEF drops, while four nHCM patients in phase 2 had shallow LVEF reductions. Commercially, the bigger threat is that if BHB-1893 only looks comparable to Afi in nHCM, market entry will be tougher because competing CMIs may already be established and morphology-specific response remains uncertain.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.